Mydecine Innovations Group (Mydecine Innovations Group) Total Stockholders Equity : $-4.82 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Mydecine Innovations Group Total Stockholders Equity?

Mydecine Innovations Group's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-4.82 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Mydecine Innovations Group's Book Value per Share for the quarter that ended in Sep. 2023 was $-0.11. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Mydecine Innovations Group's Debt-to-Equity for the quarter that ended in Sep. 2023 was -0.84.

Mydecine Innovations Group Total Stockholders Equity Historical Data

The historical data trend for Mydecine Innovations Group's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Total Stockholders Equity Chart

Mydecine Innovations Group Annual Data

Trend

Dec13

Aug14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Stockholders Equity

Get a 7-Day Free Trial

0.05

1.39

2.78

0.17

-2.65

Mydecine Innovations Group Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Stockholders Equity	Get a 7-Day Free Trial															-3.05	-2.65	-5.89	-6.84	-4.82

Mydecine Innovations Group (OTCPK:MYCOF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Mydecine Innovations Group's Book Value per Share for the quarter that ended in Sep. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-4.817	-	0)	/	45.2075
	=	-0.11

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Mydecine Innovations Group's Debt-to-Equity for the quarter that ended in Sep. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.065	+	4.002)	/	-4.817
	=	-0.84

Mydecine Innovations Group Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mydecine Innovations Group (Mydecine Innovations Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (OTCPK:MYCOF) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

MYIG:UK 0NF0:Germany MYCO:Canada

Address

789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2

Website

https://www.mydecine.com

Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.